Date: 2025-08-19Category: Not ApplicableState: Union GovernmentCountry: India
CCI approves the proposed acquisition of certain shareholding of Micro Life Sciences Pvt. Ltd. by Platinum Jasmine A 2018 Trust (acting through its trustee Platinum Owl C 2018 RSC Limited)
**Summary:**
The Competition Commission of India (CCI) approved the proposed acquisition of a certain shareholding of Micro Life Sciences Pvt. Ltd. by Platinum Jasmine A 2018 Trust, acting through its trustee Platinum Owl C 2018 RSC Limited. The proposed combination involves Platinum Jasmine A 2018 Trust (the Acquirer) subscribing to new equity shares issued by Micro Life Sciences Pvt. Ltd. (the Target) and acquiring existing equity shares from Bilakhia Holdings Pvt. Ltd., collectively amounting to approximately 3.06% shareholding in the Target.
The Acquirer, an investment entity owned and controlled by the Abu Dhabi Investment Authority, has investments in India but does not conduct any direct business activities or maintain a physical presence in the country.
The Target, Micro Life Sciences Pvt. Ltd., along with its subsidiaries, manufactures and sells medical devices (including stents, catheters, heart valves, orthopedic implants, and endosurgery products), in-vitro diagnostic analyzers and reagents, and self-testing kits (including COVID and pregnancy tests) in India. The company is also involved in B2C sales of specialized medical devices to hospitals and has R&D facilities for in-vitro diagnostic, orthopedic, endosurgery, and cardiovascular solutions.
A detailed order from the Commission will be released subsequently. This information was posted by PIB Delhi on August 19, 2025, at 8:31 PM (Release ID: 2158151).
Key Entities Referenced
Competition Commission of India: Regulatory body that approved the acquisition.
Micro Life Sciences Pvt. Ltd.: Target company being acquired.
Platinum Jasmine A 2018 Trust: Acquirer of the shareholding in Micro Life Sciences Pvt. Ltd.
Platinum Owl C 2018 RSC Limited: Trustee of Platinum Jasmine A 2018 Trust.
Bilakhia Holdings Pvt. Ltd.: Company selling equity shares of Micro Life Sciences Pvt. Ltd.
Abu Dhabi Investment Authority: Entity that owns and controls the Acquirer (Platinum Jasmine A 2018 Trust).
India: Country where Acquirer has made investments and Target operates
COVID selftest kits: One of the self-testing kits manufactured by Micro Life Sciences Pvt. Ltd.
Competition Commission of India
CCI approves the proposed acquisition of certain
shareholding of Micro Life Sciences Pvt. Ltd. by
Platinum Jasmine A 2018 Trust (acting through its
trustee Platinum Owl C 2018 RSC Limited)
Posted On: 19 AUG 2025 8:31PM by PIB Delhi
The Competition Commission of India has approved the proposed acquisition of certain shareholding of
Micro Life Sciences Pvt. Ltd. by Platinum Jasmine A 2018 Trust (acting through its trustee Platinum Owl C
2018 RSC Limited).
The proposed combination entails the Acquirer to - (i) subscribe to certain equity shares proposed to be issued
by the Target; and (ii) acquire certain equity shares of the Target from Bilakhia Holdings Pvt. Ltd., amounting
to approximately 3.06% shareholding in the Target (collectively, referred to as the Proposed Combination).
Platinum Jasmine A 2018 Trust (acting through its trustee Platinum Owl C 2018 RSC Limited) (Acquirer) is
an investment entity owned and controlled by the Abu Dhabi Investment Authority. The Acquirer has made
certain investments in India. Apart from making investments in India, it does not carry out any business
activities in India directly and does not have a physical presence in India.
Micro Life Sciences Pvt. Ltd. (Target) and its subsidiaries are primarily engaged in manufacture and sale of:
(a) medical devices such as stents, percutaneous transluminal coronary angioplasty catheters, heart valves,
orthopaedic implants, and endo-surgery products such as sutures, staplers, meshes and intrauterine devices; (b)
in-vitro diagnostics analyzers and reagents; and (c) self-testing kits, such as COVID self-test kits and
pregnancy test kits, in India. They are also engaged in the B2C sale of certain specialized medical devices such
as surgical robots and ultrasonic energy devices to hospitals and have research and development facilities for
in-vitro diagnostic, orthopaedic, endo-surgery and cardiovascular solutions.
Detailed order of the Commission will follow.
****
NB/AD
(Release ID: 2158151)